Building A US Business: Celltrion’s New CCO Talks Strategy

Biosimilars Specialist Moves To Direct Sales Model In US With Three Key Launches

With Celltrion transitioning to a direct sales model in the US after previously partnering with other firms to market its biosimilars, the company’s new US chief commercial officer, Tom Nusbickel, talks about how the firm is gearing up to launch three key products.

Jigsaw puzzle of US flag
Tom Nusbickel has been piecing together Celltrion’s US operation • Source: Shutterstock

Celltrion is not new to the US biosimilars market. For years, the company has partnered with other leading firms – including Pfizer Inc. and Teva Pharmaceutical Industries Ltd. – to market its biosimilars in the US, notching up achievements that have included launching the first US biosimilar monoclonal antibody, with Inflectra (infliximab-dyyb), as well as offering the first Rituxan (rituximab) rival to boast a key rheumatoid arthritis indication. (Also see "Teva And Celltrion Gain Arthritis Advantage On Rituximab" - Generics Bulletin, 6 May, 2020.)

However, a significant change is now on the horizon for Celltrion, as it transitions to a direct sales model for...

More from C-Suite Speaks

More from Leadership